Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Encompass Health (EHC) Delivers Strong Q3 2026 Results with +8.9% Revenue Growth and Raised Guidance

Encompass Health (EHC) Delivers Strong Q3 2026 Results with +8.9% Revenue Growth and Raised Guidance

Key Takeaways

  • Encompass Health reported third-quarter 2026 net operating revenue of $1.61 billion, up 8.9% year over year (YoY).
  • Adjusted earnings per share (EPS) came in at $1.52, comfortably above the Wall Street consensus estimate of $1.36.
  • Management raised its full-year 2026 guidance for both net operating revenue and adjusted EPS.
  • Strong demand for inpatient rehabilitation, supported by capacity expansion and easing labor costs, underpinned the results.
  • For more context on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
  • Explore Trending AI Robots to see AI-driven trading strategies currently active in the market.

Earnings Context and Why It Matters

Encompass Health is the largest owner and operator of inpatient rehabilitation facilities (IRFs) in the United States, providing hospital-level rehabilitative care to patients recovering from stroke, neurological conditions, and other serious injuries. Its results are closely watched as a barometer of healthcare demand tied to an aging U.S. population. The third quarter follows consecutive beats earlier in 2026, when rising patient acuity and improved staffing retention drove revenue and margin gains. Investors are watching whether that momentum can persist, particularly as the company navigates evolving Medicare Advantage dynamics and expands capacity through new and small-format hospitals. I checked comparable names in the space using Tickeron’s AI Screener to see how EHC stacks up on key metrics.

Reported Results

For the third quarter ended September 30, 2026, Encompass Health reported net operating revenue of $1.61 billion, an 8.9% increase from $1.48 billion in the prior-year period and slightly above the consensus estimate of approximately $1.60 billion. Adjusted EPS reached $1.52, exceeding the $1.36 analysts had expected.

For the first nine months of 2026, net operating revenue totaled $4.79 billion, up from $4.39 billion a year earlier. Management raised its full-year 2026 outlook, now projecting net operating revenue of $6.45 billion to $6.50 billion (up from $6.41 billion to $6.49 billion) and adjusted EPS of $6.23 to $6.37 (up from $6.02 to $6.25). The quarter reflected continued strength in patient demand and improved operating leverage, with the company describing itself as "very pleased" with its performance.

Market Reaction and Investor Sentiment

Encompass Health's results arrived ahead of expectations on both the top and bottom lines, with the raised full-year guidance adding to a generally constructive setup heading into the print. The beat was driven by resilient demand for inpatient rehabilitation and continued improvement in labor efficiency, factors analysts have repeatedly cited as key to the company's margin trajectory. Wall Street sentiment on the stock remains broadly favorable, with the analyst community carrying a consensus Strong Buy rating and an average price target well above the shares' recent trading range. Investors will be parsing the earnings call for details on patient acuity trends and the pace of capacity additions, both of which are central to the stock's near-term narrative.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should focus on several themes. First, capacity expansion remains a core growth lever: the company is adding beds to existing hospitals and rolling out a small-format hospital strategy, including a hub-and-spoke model designed to reach markets where larger facilities may not be economical. The pace and returns on these additions will shape multi-year revenue growth.

Second, patient acuity, or the clinical complexity of admitted patients, is a key margin driver. Elevated acuity has supported revenue per discharge; any normalization could moderate growth. Third, Medicare Advantage (MA) reimbursement remains an area to watch, particularly the effectiveness of the company's admit-and-appeal strategy in converting initially denied admissions into paid care.

Finally, regulatory and cost dynamics matter. The Centers for Medicare & Medicaid Services (CMS) continue to expand value-based care programs, while labor costs have trended favorably as nurse turnover improves and premium labor spend declines. Sustained margin expansion will depend on balancing these factors with ongoing investment in growth. From what I see, these elements will determine whether the recent momentum holds into 2027.

Integrating Tickeron’s AI Tools into My Research

I often turn to Tickeron’s AI Screener when evaluating healthcare names like this one. It lets me quickly filter for stocks showing similar technical patterns or fundamental strength, helping me build context around earnings beats and sector trends without spending hours on manual screens. The tool has become a regular part of how I cross-check ideas before diving deeper into the numbers.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: EHC

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


EHC in -4.06% downward trend, falling for three consecutive days on November 19, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where EHC declined for three days, in 159 of 289 cases, the price declined further within the following month. The odds of a continued downward trend are 55%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for EHC moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 19 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EHC as a result. In 45 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 51%.

The Moving Average Convergence Divergence Histogram (MACD) for EHC turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 22 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 47%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

EHC moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +0.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where EHC advanced for three days, in 198 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.

EHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 221 of 342 cases where EHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

The Tickeron SMR rating for this company is 38 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. EHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.223) is normal, around the industry mean (204.532). P/E Ratio (22.113) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.610) is also within normal values, averaging (2.498). Dividend Yield (0.006) settles around the average of (0.153) among similar stocks. P/S Ratio (2.021) is also within normal values, averaging (2.688).

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -12%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was 0%. CHE experienced the highest price growth at 0%, while NIVF experienced the biggest fall at -88%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 102% and the average quarterly volume growth was 58%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 49
Price Growth Rating: 59
SMR Rating: 66
Profit Risk Rating: 83
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an operator of inpatient rehabilitation hospitals

Industry HospitalNursingManagement

Industry
Hospital Or Nursing Management
Address
9001 Liberty Parkway
Phone
+1 205 967-7116
Employees
42300
Web
https://www.encompasshealth.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.